190 related articles for article (PubMed ID: 34963005)
21. Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy.
Domchek SM; Aghajanian C; Shapira-Frommer R; Schmutzler RK; Audeh MW; Friedlander M; Balmaña J; Mitchell G; Fried G; Stemmer SM; Hubert A; Rosengarten O; Loman N; Robertson JD; Mann H; Kaufman B
Gynecol Oncol; 2016 Feb; 140(2):199-203. PubMed ID: 26723501
[TBL] [Abstract][Full Text] [Related]
22. Factors associated with clonal hematopoiesis and interaction with marrow environment.
Nannya Y
J Bone Miner Metab; 2023 May; 41(3):380-387. PubMed ID: 36346484
[TBL] [Abstract][Full Text] [Related]
23. Clonal Hematopoiesis Mutations Are Present in Atherosclerotic Lesions in Peripheral Artery Disease.
Büttner P; Böttner J; Krohn K; Baber R; Platzbecker U; Cross M; Desch S; Thiele H; Steiner S; Scheinert D; Metzeler KH; Branzan D
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835370
[TBL] [Abstract][Full Text] [Related]
24. Full spectrum of clonal haematopoiesis-driver mutations in chronic heart failure and their associations with mortality.
Kiefer KC; Cremer S; Pardali E; Assmus B; Abou-El-Ardat K; Kirschbaum K; Dorsheimer L; Rasper T; Berkowitsch A; Serve H; Dimmeler S; Zeiher AM; Rieger MA
ESC Heart Fail; 2021 Jun; 8(3):1873-1884. PubMed ID: 33779075
[TBL] [Abstract][Full Text] [Related]
25. Clonal hematopoiesis in patients with stem cell mobilization failure: a nested case-control study.
Hazenberg CLE; de Graaf AO; Mulder R; Bungener LB; van Bergen MGJM; Mulder AB; Choi G; Schuringa JJ; de Groot MR; Vellenga E; Jansen JH; Huls G; van Zeventer IA
Blood Adv; 2023 Apr; 7(7):1269-1278. PubMed ID: 36219593
[TBL] [Abstract][Full Text] [Related]
26. Causes of Clonal Hematopoiesis: a Review.
Joo L; Bradley CC; Lin SH; Scheet PA; Nead KT
Curr Oncol Rep; 2023 Mar; 25(3):211-220. PubMed ID: 36719597
[TBL] [Abstract][Full Text] [Related]
27. Impact of carboplatin hypersensitivity and desensitization on patients with recurrent ovarian cancer.
Altwerger G; Florsheim EB; Menderes G; Black J; Schwab C; Gressel GM; Nelson WK; Carusillo N; Passante T; Huang G; Litkouhi B; Azodi M; Silasi DA; Santin A; Schwartz PE; Ratner ES
J Cancer Res Clin Oncol; 2018 Dec; 144(12):2449-2456. PubMed ID: 30255380
[TBL] [Abstract][Full Text] [Related]
28. TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma.
Brachova P; Mueting SR; Carlson MJ; Goodheart MJ; Button AM; Mott SL; Dai D; Thiel KW; Devor EJ; Leslie KK
Int J Oncol; 2015 Feb; 46(2):607-18. PubMed ID: 25385265
[TBL] [Abstract][Full Text] [Related]
29. Association of clonal haematopoiesis with severe postoperative complications in patients undergoing radical oesophagectomy.
Wang H; Yan H; Chen W; Tang H; Pei Y; Shan Q; Cang J; Miao C; Tan L; Tan L
Br J Anaesth; 2024 Feb; 132(2):277-284. PubMed ID: 38044238
[TBL] [Abstract][Full Text] [Related]
30. Clonal hematopoiesis of indeterminate potential-associated mutations and risk of comorbidities in patients with myelodysplastic syndrome.
Naqvi K; Sasaki K; Montalban-Bravo G; Alfonso Pierola A; Yilmaz M; Short N; Assi R; Jabbour E; Ravandi F; Kadia T; Pierce S; Takahashi K; Nogueras Gonzalez G; Kanagal-Shamanna R; Patel K; Soltysiak KA; Kantarjian HM; Garcia-Manero G
Cancer; 2019 Jul; 125(13):2233-2241. PubMed ID: 30861111
[TBL] [Abstract][Full Text] [Related]
31. TP53 K351N mutation-associated platinum resistance after neoadjuvant chemotherapy in patients with advanced ovarian cancer.
Zhang GN; Liu H; Huang JM; Wang L; Zhao JS; Li C; Mi K; Zhu Y; Cheng J; Zha X
Gynecol Oncol; 2014 Mar; 132(3):752-7. PubMed ID: 24463159
[TBL] [Abstract][Full Text] [Related]
32. Association of PARP inhibitor treatment on the prevalence and progression of clonal hematopoiesis in patients with advanced prostate cancer.
Marshall CH; Gondek LP; Daniels V; Lu C; Pasca S; Xie J; Markowski MC; Paller CJ; Sena LA; Denmeade SR; Luo J; Antonarakis ES
Prostate; 2024 Jul; 84(10):954-958. PubMed ID: 38641986
[TBL] [Abstract][Full Text] [Related]
33. Prognostic relevance of clonal hematopoiesis in myeloid neoplastic transformation in patients with follicular lymphoma treated with radioimmunotherapy.
Xie Z; Lasho T; Khurana A; Ferrer A; Finke C; Mangaonkar AA; Ansell S; Fernandez J; Shah MV; Al-Kali A; Gangat N; Abeykoon J; Witzig TE; Patnaik MM
Haematologica; 2024 Feb; 109(2):509-520. PubMed ID: 37646653
[TBL] [Abstract][Full Text] [Related]
34. Clonal haematopoiesis in chronic ischaemic heart failure: prognostic role of clone size for DNMT3A- and TET2-driver gene mutations.
Assmus B; Cremer S; Kirschbaum K; Culmann D; Kiefer K; Dorsheimer L; Rasper T; Abou-El-Ardat K; Herrmann E; Berkowitsch A; Hoffmann J; Seeger F; Mas-Peiro S; Rieger MA; Dimmeler S; Zeiher AM
Eur Heart J; 2021 Jan; 42(3):257-265. PubMed ID: 33241418
[TBL] [Abstract][Full Text] [Related]
35. TP53 gene status and human papilloma virus infection in response to platinum plus taxane-based chemotherapy of epithelial ovarian carcinomas.
Malisic E; Jankovic R; Jakovljevic K; Radulovic S
J BUON; 2011; 16(4):701-7. PubMed ID: 22331725
[TBL] [Abstract][Full Text] [Related]
36. Associations of clonal hematopoiesis with recurrent vascular events and death in patients with incident ischemic stroke.
Arends CM; Liman TG; Strzelecka PM; Kufner A; Löwe P; Huo S; Stein CM; Piper SK; Tilgner M; Sperber PS; Dimitriou S; Heuschmann PU; Hablesreiter R; Harms C; Bullinger L; Weber JE; Endres M; Damm F
Blood; 2023 Feb; 141(7):787-799. PubMed ID: 36441964
[TBL] [Abstract][Full Text] [Related]
37. Prognosis of patients with BRCA1-associated ovarian carcinomas depends on TP53 accumulation status in tumor cells.
Rzepecka IK; Szafron LM; Stys A; Felisiak-Golabek A; Podgorska A; Timorek A; Sobiczewski P; Pienkowska-Grela B; El-Bahrawy M; Kupryjanczyk J
Gynecol Oncol; 2017 Feb; 144(2):369-376. PubMed ID: 27939982
[TBL] [Abstract][Full Text] [Related]
38. Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly.
Zink F; Stacey SN; Norddahl GL; Frigge ML; Magnusson OT; Jonsdottir I; Thorgeirsson TE; Sigurdsson A; Gudjonsson SA; Gudmundsson J; Jonasson JG; Tryggvadottir L; Jonsson T; Helgason A; Gylfason A; Sulem P; Rafnar T; Thorsteinsdottir U; Gudbjartsson DF; Masson G; Kong A; Stefansson K
Blood; 2017 Aug; 130(6):742-752. PubMed ID: 28483762
[TBL] [Abstract][Full Text] [Related]
39. Cancer therapy shapes the fitness landscape of clonal hematopoiesis.
Bolton KL; Ptashkin RN; Gao T; Braunstein L; Devlin SM; Kelly D; Patel M; Berthon A; Syed A; Yabe M; Coombs CC; Caltabellotta NM; Walsh M; Offit K; Stadler Z; Mandelker D; Schulman J; Patel A; Philip J; Bernard E; Gundem G; Ossa JEA; Levine M; Martinez JSM; Farnoud N; Glodzik D; Li S; Robson ME; Lee C; Pharoah PDP; Stopsack KH; Spitzer B; Mantha S; Fagin J; Boucai L; Gibson CJ; Ebert BL; Young AL; Druley T; Takahashi K; Gillis N; Ball M; Padron E; Hyman DM; Baselga J; Norton L; Gardos S; Klimek VM; Scher H; Bajorin D; Paraiso E; Benayed R; Arcila ME; Ladanyi M; Solit DB; Berger MF; Tallman M; Garcia-Closas M; Chatterjee N; Diaz LA; Levine RL; Morton LM; Zehir A; Papaemmanuil E
Nat Genet; 2020 Nov; 52(11):1219-1226. PubMed ID: 33106634
[TBL] [Abstract][Full Text] [Related]
40. Clonal hematopoiesis in angioimmunoblastic T-cell lymphoma with divergent evolution to myeloid neoplasms.
Lewis NE; Petrova-Drus K; Huet S; Epstein-Peterson ZD; Gao Q; Sigler AE; Baik J; Ozkaya N; Moskowitz AJ; Kumar A; Horwitz SM; Zhang Y; Arcila ME; Levine RL; Roshal M; Dogan A; Xiao W
Blood Adv; 2020 May; 4(10):2261-2271. PubMed ID: 32442302
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
